Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-13 7:09 pm Purchase | 2025-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 12,668,344 5.600% | 62,450 (+0.50%) | Filing History |
| 2025-11-13 7:06 pm Sale | 2025-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | Capital World Investors | 0 0.000% | -12,265,330 (Position Closed) | Filing History |
| 2025-11-12 4:37 pm Purchase | 2025-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | David D. Chang, M.D., Ph.D. | 11,234,918 4.900% | 98,190 (+0.88%) | Filing History |
| 2025-08-12 4:57 pm Purchase | 2025-06-30 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 12,605,894 5.700% | 62,450 (+0.50%) | Filing History |
| 2025-08-08 8:13 pm Purchase | 2025-06-30 | 13G | Allogene Therapeutics, Inc. ALLO | David D. Chang, M.D., Ph.D. | 11,136,728 5.000% | 93,628 (+0.85%) | Filing History |
| 2025-07-16 6:02 pm Purchase | 2025-07-09 | 13G | Allogene Therapeutics, Inc. ALLO | Citadel Advisors LLC | 13,346,151 6.100% | 13,346,151 (New Position) | Filing History |
| 2025-05-13 11:44 am Purchase | 2025-03-31 | 13G | Allogene Therapeutics, Inc. ALLO | Capital World Investors | 12,265,330 5.600% | 12,265,330 (New Position) | Filing History |
| 2025-05-09 5:49 pm Purchase | 2025-03-31 | 13G | Allogene Therapeutics, Inc. ALLO | David D. Chang, M.D., Ph.D. | 11,043,100 5.000% | 138,097 (+1.27%) | Filing History |
| 2025-05-09 5:30 pm Purchase | 2025-03-31 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 12,543,444 5.700% | 149,877 (+1.21%) | Filing History |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | Allogene Therapeutics, Inc. ALLO | BlackRock Inc. BLK | 11,450,079 5.300% | -6,322,666 (-35.58%) | Filing History |
| 2025-03-07 10:01 am Sale | 2025-02-28 | 13G | Allogene Therapeutics, Inc. ALLO | FMR LLC | 10,225,851 4.900% | -13,546,144 (-56.98%) | Filing History |
| 2025-02-14 09:02 am Purchase | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Lynx1 Capital Management LP | 10,874,723 5.200% | 10,874,723 (New Position) | Filing History |
| 2025-02-13 4:31 pm Purchase | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 12,393,567 5.800% | 2,497,664 (+25.24%) | Filing History |
| 2025-02-13 4:29 pm Purchase | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | David D. Chang, M.D., Ph.D. | 10,905,003 5.100% | 940,656 (+9.44%) | Filing History |
| 2025-02-12 09:16 am Sale | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | FMR LLC | 23,771,995 11.300% | -1,469,504 (-5.82%) | Filing History |
| 2024-11-12 1:26 pm Unchanged | 2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | The Vanguard Group | 8,327,699 3.980% | 0 (Unchanged) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | BlackRock Inc. BLK | 17,772,745 8.500% | 0 (Unchanged) | Filing History |
| 2024-11-04 10:57 am Sale | 2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | The Vanguard Group | 8,327,699 3.980% | -703,126 (-7.79%) | Filing History |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | BlackRock Inc. BLK | 17,772,745 8.500% | 7,770,941 (+77.70%) | Filing History |
| 2024-02-14 4:36 pm Purchase | 2023-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 9,895,903 5.800% | 1,037,042 (+11.71%) | Filing History |